Safety and Efficacy of Imatinib, Nilotinib, and Artesunate in COVID-19 Patients: A Systematic Review of Current Evidence
- 作者: Ghavimehr E.1,2, Zand A.1,2, SeyedAlinaghi S.A.2, Karimi A.3, Zaferani Arani H.1, Mirzapour P.2, Pashaei Z.2, Mehraeen E.2,4, Dadras O.2,5
-
隶属关系:
- School of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
- Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
- Department of Health Information Management, Arabdil University of Medical Sciences, Khalkhal, Iran
- Department of Global Public Health and Primary Care, Graduate School of Medicine, Bergen University, Bergen, Norway
- 期: 卷 22, 编号 1 (2024)
- 栏目: Medicine
- URL: https://jdigitaldiagnostics.com/2211-3525/article/view/642299
- DOI: https://doi.org/10.2174/2211352521666230714160740
- ID: 642299
如何引用文章
全文:
详细
Introduction:There is a need for better treatment options against COVID-19. This systematic review aimed to assess the safety and efficacy of imatinib and nilotinib, two tyrosine kinase inhibitors (TKIs), as well as artesunate (an anti-malarial agent), whose multilayer activ-ities against SARS, MERS, and SARS-CoV-2 pathogenesis have been suggested in laboratory and observational studies.
Methods:A comprehensive search strategy targeting relevant literature on PubMed, Scopus, and Web of Science online databases was constructed. The retrieved records were reviewed and screened by title/abstract and full text with eligibility criteria, and the most pertinent articles were included in the final qualitative synthesis. This review adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to ensure the reliability of the results.
Results:This systematic review assessed the safety and applicability of imatinib, nilotinib, and artesunate in COVID-19 patients. The results showed not only possible anti-COVID-19 effects but also acceptable safety for both generic users with comorbidities with COVID-19 and off-label use in other COVID-19 patients. Promising results were also reported enhancing the sur-vival of COVID-19 patients.
Conclusion:A double-blinded multicenter randomized controlled trial found survival benefits for imatinib with no significant treatment-related adverse events. However, no clinical trials or large observational studies exist for artesunate and nilotinib, and the evidence relies only on case reports and case series. Molecular mechanisms revealed in preclinical studies support the possible benefits of these medications in COVID-19 treatment. However, the scarcity of reliable evidence requires further studies on possible COVID-19 treatments, including but not limited to artesunate, nilotinib, and imatinib. Nevertheless, these drugs' lack of serious adverse events suggests their safe use for other indications during the COVID-19 pandemic.
作者简介
Ehsan Ghavimehr
School of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Iranian Research Center forHIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Email: info@benthamscience.net
Ali Zand
School of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Iranian Research Center forHIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Email: info@benthamscience.net
Seyed SeyedAlinaghi
Iranian Research Center forHIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Email: info@benthamscience.net
Amirali Karimi
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Email: info@benthamscience.net
Hamid Zaferani Arani
School of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Email: info@benthamscience.net
Pegah Mirzapour
Iranian Research Center forHIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Email: info@benthamscience.net
Zahra Pashaei
Iranian Research Center forHIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Email: info@benthamscience.net
Esmaeil Mehraeen
Iranian Research Center forHIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran; Department of Health Information Management,
Arabdil University of Medical Sciences, Khalkhal, Iran
编辑信件的主要联系方式.
Email: info@benthamscience.net
Omid Dadras
Iranian Research Center forHIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran; Department of Global Public Health and Primary Care, Graduate
School of Medicine, Bergen University, Bergen, Norway
Email: info@benthamscience.net
补充文件
